With stroke and dementia costing Germany €65 billion annually, nyra health raises €20 million to expand its digital neurotherapy platform

The funding round was led by Armira Growth, with continued support from existing investors Wellington Partners, Crane Venture Partners (which now manages investments for MassMutual Ventures), and EVER Pharma. This follows a €4.5 million Seed round raised in 2023.

Moritz Schöllauf, CEO and co-founder, nyra health, says: “From the outset, our goal was to make our services widely available to those affected. Everyone who needs therapy after a stroke or other neurological disease should have access to effective, individualised care – regardless of where they live or how well their own healthcare system is set up. With this round of financing, we are taking another step in this direction.”

In the wider 2025–2026 funding environment, several European health and neurology startups have also raised significant capital, highlighting continued investor interest in neurological innovation and digital care solutions.

For example, Aerska in Dublin raised around €17 million in Seed funding to develop RNA interference-based treatments for central nervous system diseases, targeting complex brain disorders. Meanwhile, EG 427, based in Paris, secured €27 million in a Series B round to advance genetic medicine programs focused on chronic neurological conditions.

Read Also - Frankenburg Technologies secures €30M to advance its missile defence systems

Early-stage companies are also attracting investment. Strolll raised approximately €12.2 million to develop augmented reality solutions for neurorehabilitation, while Neu Health secured about €1.9 million to expand AI-powered care for Parkinson’s disease and dementia. In Copenhagen, Hemi Health raised €4 million in Seed funding to scale digital therapies and clinical services for migraine, concussion, and headache disorders.

Against this backdrop, nyra health’s €20 million Series A round for its AI-based neurorehabilitation platform reflects a broader European trend of increased investment in neurological and HealthTech innovation.

Together, these funding rounds exceed €60 million, underscoring a growing and converging focus on neurological disease research, digital therapeutics, and AI-driven healthcare solutions. Investors are actively supporting both drug-focused biotech companies and software-enabled clinical platforms across the sector

Christian Figge, Managing Partner, Armira Growth, adds: “Neurological rehabilitation can be made significantly more effective through digital solutions, especially in the area of speech ability. nyra health is considered a true category creator with a proprietary AI-based solution that seamlessly connects the entire care chain – from inpatient therapy to outpatient aftercare to home use – for the first time.”

Founded in 2021 by an interdisciplinary team of specialists in neurology, machine learning, and regulatory affairs, nyra health is building an AI-driven platform for neurological rehabilitation.

Today, its solution is used in more than 100 rehabilitation clinics, integrated into the digital aftercare programme of the German Pension Insurance Fund, and accessed by patients with support from over 28 health insurance providers.

According to the company, neurological conditions such as stroke, dementia, and traumatic brain injury generate approximately €65 billion in annual costs in Germany alone. A major reason is that therapy often declines or stops after hospital discharge, creating gaps in care and leading to higher long-term expenses due to insufficient follow-up treatment and preventable health complications.

Its product, myReha, has demonstrated the ability to significantly increase therapy time while also reducing costs. Currently, 28 statutory and private insurers automatically reimburse myReha, giving more than 40 million insured individuals access to structured, AI-based home therapy supported by real-time feedback.

“We were also particularly impressed by the strong clinical evidence and deep integration into the German standard of care, which already gives nyra health access to over 40 million insured individuals. On this basis, the company is ideally positioned to define the market for digital neurorehabilitation internationally as well,” shares Christian.

At the core of nyra health’s offering is myReha, an MDR Class IIa–certified medical device designed for neurological rehabilitation. The platform enables patients to train speech, cognitive abilities, fine motor skills, and everyday functional tasks using AI-powered real-time feedback. Its specially developed speech models analyse pathological speech in detail, assessing pronunciation, word retrieval, syntax, and semantic structure. In parallel, the system continuously evaluates reaction times, error patterns, and overall training dynamics.

Using this data, the therapy programme automatically adjusts to each patient’s performance level, fatigue, and recovery progress. In a randomized controlled trial, patients who used myReha alongside standard therapy achieved significantly greater improvements in cognitive and language functions compared to those receiving standard therapy alone.

For clinicians, the nyra insights dashboard provides structured oversight and control. Therapists can monitor language development, therapy intensity, and progress curves in real time, adapt treatment plans accordingly, and generate documentation automatically. This is further enhanced by an AI-powered Content Studio, which dynamically creates personalised therapy materials tailored to individual patient performance data.

Following the recent funding announcement, the company plans to onboard additional clinic groups across the DACH region and strategically expand reimbursement frameworks in Germany, Austria, and Switzerland. At the same time, it is preparing for entry into the US market.

In parallel, nyra health continues to invest in advancing its technology platform, particularly by developing multimodal AI models for therapeutic interaction and diagnostics. These innovations are part of a €4.2 million funded research project and are being scientifically validated in collaboration with leading research universities in the United States.